List of Rezlidhia drug patents
Rezlidhia is owned by Rigel Pharms Inc.
Rezlidhia contains Olutasidenib.
Rezlidhia has a total of 10 drug patents out of which 0 drug patents have expired.
Rezlidhia was authorised for market use on 01 December, 2022.
Rezlidhia is available in capsule;oral dosage forms.
Rezlidhia can be used as a method of treating a cancer where the cancer is acute myeloid leukemia (aml), a method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml), a method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation.
Drug patent challenges can be filed against Rezlidhia from 2026-12-01.
The generics of Rezlidhia are possible to be released after 16 May, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9834539 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(12 years from now) | |
| US10532047 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11498913 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(12 years from now) | |
| US10414752 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(12 years from now) | |
| US10550098 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(12 years from now) | |
| US11376246 | RIGEL PHARMS INC | Inhibiting mutant IDH-1 |
May, 2039
(15 years from now) | |
| US10959994 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(15 years from now) | |
| US11013734 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(15 years from now) | |
| US11497743 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(15 years from now) | |
| US11013733 | RIGEL PHARMS INC | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 1, 2027 |
| Orphan Drug Exclusivity (ODE) | Dec 1, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 2026-12-01
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is ac...
Dosage: CAPSULE;ORAL
REZLIDHIA family patents
56
United States
6
European Union
5
Australia
4
Spain
4
Morocco
4
Mexico
3
Canada
3
Japan
3
Israel
2
Denmark
2
RS
2
Poland
2
China
2
EA
2
Croatia
2
Portugal
2
Lithuania
2
Slovenia
1
Philippines
1
Malaysia
1
Brazil
1
Singapore
1
Argentina
1
ME
1
New Zealand
1
Korea, Republic of
1
Cyprus
1
Peru
1
Chile
1
Taiwan
1
Ecuador
1
South Africa
1
Colombia
1
Saudi Arabia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic